Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited

SHSE:600329 Stock Report

Market Cap: CN¥21.5b

Tianjin Pharmaceutical Da Ren Tang Group Past Earnings Performance

Past criteria checks 2/6

Tianjin Pharmaceutical Da Ren Tang Group has been growing earnings at an average annual rate of 10.9%, while the Pharmaceuticals industry saw earnings growing at 9.1% annually. Revenues have been growing at an average rate of 5.1% per year. Tianjin Pharmaceutical Da Ren Tang Group's return on equity is 14.3%, and it has net margins of 11.6%.

Key information

10.9%

Earnings growth rate

10.8%

EPS growth rate

Pharmaceuticals Industry Growth10.9%
Revenue growth rate5.1%
Return on equity14.3%
Net Margin11.6%
Last Earnings Update30 Sep 2024

Recent past performance updates

Recent updates

Tianjin Pharmaceutical Da Ren Tang Group (SHSE:600329) Could Easily Take On More Debt

Dec 18
Tianjin Pharmaceutical Da Ren Tang Group (SHSE:600329) Could Easily Take On More Debt

Are Investors Undervaluing Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited (SHSE:600329) By 48%?

Oct 27
Are Investors Undervaluing Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited (SHSE:600329) By 48%?

Why Investors Shouldn't Be Surprised By Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited's (SHSE:600329) 36% Share Price Surge

Oct 08
Why Investors Shouldn't Be Surprised By Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited's (SHSE:600329) 36% Share Price Surge

Some Shareholders Feeling Restless Over Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited's (SHSE:600329) P/E Ratio

Jul 26
Some Shareholders Feeling Restless Over Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited's (SHSE:600329) P/E Ratio

Tianjin Pharmaceutical Da Ren Tang Group (SHSE:600329) Has A Rock Solid Balance Sheet

Jul 05
Tianjin Pharmaceutical Da Ren Tang Group (SHSE:600329) Has A Rock Solid Balance Sheet

Fewer Investors Than Expected Jumping On Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited (SHSE:600329)

Apr 18
Fewer Investors Than Expected Jumping On Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited (SHSE:600329)

Tianjin Pharmaceutical Da Ren Tang Group (SHSE:600329) Has A Rock Solid Balance Sheet

Mar 18
Tianjin Pharmaceutical Da Ren Tang Group (SHSE:600329) Has A Rock Solid Balance Sheet

Revenue & Expenses Breakdown

How Tianjin Pharmaceutical Da Ren Tang Group makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

SHSE:600329 Revenue, expenses and earnings (CNY Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 248,0409322,651197
30 Jun 248,0999222,575179
31 Mar 248,0509152,503184
31 Dec 238,2229872,527185
30 Sep 238,4799912,562147
30 Jun 238,5631,1162,551150
31 Mar 238,5141,0632,490158
31 Dec 228,2498622,356153
30 Sep 227,1188371,910159
30 Jun 227,0427751,932150
31 Mar 226,9707561,929151
31 Dec 216,9087691,935161
30 Sep 216,9998461,911168
30 Jun 216,9548011,839169
31 Mar 216,7757051,843158
31 Dec 206,6046621,821149
30 Sep 206,7736571,934128
30 Jun 206,7516022,054126
31 Mar 206,8966052,126133
31 Dec 196,9946262,194133
30 Sep 196,8476062,174126
30 Jun 196,7805952,106118
31 Mar 196,4975782,043102
31 Dec 186,3595622,004101
30 Sep 186,0845172,01290
30 Jun 185,8145121,94387
31 Mar 185,8235161,82199
31 Dec 175,6894761,73379
30 Sep 175,7474331,74044
30 Jun 175,9524431,74829
31 Mar 176,0814381,7210
31 Dec 166,2434241,6920
30 Sep 166,8454671,5920
30 Jun 166,9974711,5640
31 Mar 167,1044521,6220
31 Dec 157,0814511,6330
30 Sep 157,0264361,7240
30 Jun 157,1143981,7450
31 Mar 157,1563751,7510
31 Dec 147,0873581,7050
30 Sep 146,6213721,6130
30 Jun 146,2673611,5550
31 Mar 146,1133361,5050
31 Dec 136,0103521,5080

Quality Earnings: 600329 has high quality earnings.

Growing Profit Margin: 600329's current net profit margins (11.6%) are lower than last year (11.7%).

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: 600329's earnings have grown by 10.9% per year over the past 5 years.

Accelerating Growth: 600329's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: 600329 had negative earnings growth (-5.9%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (-2.5%).

Return on Equity

High ROE: 600329's Return on Equity (14.3%) is considered low.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/23 08:47
End of Day Share Price 2024/12/23 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited is covered by 9 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Yalei YanBohai Securities Co., Ltd.
Chengzhi ChenCGS International
Shanshan LiChina Merchants Securities Co. Ltd.